பல்கலைக்கழகம் ஆஃப் டொராண்டோ பிரிவு சிறுநீரகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பல்கலைக்கழகம் ஆஃப் டொராண்டோ பிரிவு சிறுநீரகம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பல்கலைக்கழகம் ஆஃப் டொராண்டோ பிரிவு சிறுநீரகம் Today - Breaking & Trending Today

LIDDS AB: European Urology Focus has accepted a scientific article describing LIDDS Phase IIb study results with Liproca Depot

(1)
UPPSALA, SWEDEN - LIDDS AB (publ) announces that a scientific article will be published in the highly ranked European Urology Focus describing LIDDS clinical Phase IIb study, LPC-004, and its clinical results. The study met both primary and secondary endpoints by confirming efficacy and safety with Liproca Depot given as intraprostatic injection in low- and intermediate risk prostate cancer patients.
We are pleased that this manuscript is accepted in a highly recognized scientific paper and the results further validates NanoZolid as being an innovative technology platform, said Monica Wallter, CEO of LIDDS.
Liproca Depot, which comprises the NanoZolid technology combined with an antiandrogen drug (2-hydroxyflutamide) injected into the prostate, met both the primary and secondary endpoints in the study. Efficacy was shown by a maintained PSA decrease over 6 months, lower prostate volume and unchanged or improved MRI results. No hormonal side effects were shown. L ....

Uppsala Lan , Laurence Klotz , Monica Wallter , University Of Toronto Division Urology , European Urology Focus , Liproca Depot , Professor Laurence Klotz , Toronto Division , லாரன்ஸ் கிலோட்ஜ , பல்கலைக்கழகம் ஆஃப் டொராண்டோ பிரிவு சிறுநீரகம் , ஐரோப்பிய சிறுநீரகம் கவனம் , ப்ரொஃபெஸர் லாரன்ஸ் கிலோட்ஜ , டொராண்டோ பிரிவு ,

Investegate |LIDDS AB Announcements | LIDDS AB: European Urology Focus has accepted a scientific article describing LIDDS Phase IIb study results with Liproca® Depot

LIDDS AB
European Urology Focus has accepted a scientific article describing LIDDS Phase IIb study results with Liproca® Depot
European Urology Focus has accepted a scientific article describing LIDDS Phase IIb study results with Liproca® Depot
UPPSALA, SWEDEN – LIDDS AB (publ) announces that a scientific article will be published in the highly ranked European Urology Focus describing LIDDS clinical Phase IIb study, LPC-004, and its clinical results. The study met both primary and secondary endpoints by confirming efficacy and safety with Liproca Depot given as intraprostatic injection in low- and intermediate risk prostate cancer patients.
“We are pleased that this manuscript is accepted in a highly recognized scientific paper and the results further validates NanoZolid® as being an innovative technology platform,” said Monica Wallter, CEO of LIDDS. ....

Uppsala Lan , Laurence Klotz , Monica Wallter , University Of Toronto Division Urology , European Urology Focus , Liproca Depot , Professor Laurence Klotz , Toronto Division , Nasdaq First North , Certified Adviser , லாரன்ஸ் கிலோட்ஜ , பல்கலைக்கழகம் ஆஃப் டொராண்டோ பிரிவு சிறுநீரகம் , ஐரோப்பிய சிறுநீரகம் கவனம் , ப்ரொஃபெஸர் லாரன்ஸ் கிலோட்ஜ , டொராண்டோ பிரிவு , நாஸ்டாக் முதல் வடக்கு ,